Umoja Biopharma Revenue and Competitors

Seattle, WA USA

Location

#5878

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Umoja Biopharma's estimated annual revenue is currently $48.2M per year.(i)
  • Umoja Biopharma's estimated revenue per employee is $201,000
  • Umoja Biopharma's total funding is $263M.

Employee Data

  • Umoja Biopharma has 240 Employees.(i)
  • Umoja Biopharma grew their employee count by 26% last year.

Umoja Biopharma's People

NameTitleEmail/Phone
1
Co-founder and CTOReveal Email/Phone
2
Co-founder & CEOReveal Email/Phone
3
SVP, Translational SciencesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15.1M7519%N/AN/A
#2
$0.8M8-50%N/AN/A
#3
$114M5677%N/AN/A
#4
$19.3M9613%N/AN/A
#5
$5.4M2717%N/AN/A
#6
$17.7M88-45%N/AN/A
#7
$13.9M6910%N/AN/A
#8
$5.4M27-10%N/AN/A
#9
$0.8M80%$22MN/A
#10
$5.4M2729%N/AN/A
Add Company

What Is Umoja Biopharma?

Umoja is developing a new approach to cancer therapy that retools a patient's immune system in vivo, enhancing the body's natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

keywords:N/A

$263M

Total Funding

240

Number of Employees

$48.2M

Revenue (est)

26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Umoja Biopharma News

2022-04-06 - Umoja Biopharma Presents Data on its iPSC-Based Cell ...

Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting...

2022-03-22 - Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors

Seattle biotech clout: Affini-T joins the ranks of cell therapy companies ... Umoja Biopharma recently raised $263 million in Series A and B...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$65.5M242N/AN/A
#2
$54.9M24322%$82M
#3
$72.2M24314%N/A
#4
$72.2M2436%N/A
#5
$37.6M244N/AN/A